Company Analysis

Supernus Pharmaceuticals, Inc. (SUPN)

SUPN · Pharmaceutical Preparations · Rockville, MD · filing with the SEC since 2006
Grade5.9
◀ Past 5.2● Present 7.1▶ Future 5.0

Who runs Supernus Pharmaceuticals, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Khattar Jack A.
President, CEO. First filing Apr 2012, latest Nov 4, 2026, 32 filings in all.
Officers reporting now
6
of 11 people with a filing in the last fifteen months
Directors reporting now
5
19 people on the record since 2012
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Khattar Jack A.President, CEOApr 2012Nov 4, 20263 · $1.8M
Dec Timothy CSenior Vice-President & CFOAug 2021Nov 4, 2026none
Mottola FrankSVP, Chief Tech. Ops. OfficerFeb 2020Nov 4, 20263 · $1.1M
Rubin JonathanSVP, Chief Medical OfficerJan 2021Nov 4, 2026none
Bhatt Padmanabh P.Sr. VP of IP, CSOApr 2012Nov 4, 20267 · $5.4M
Horich William ToddSVP, Commercial OperationsMar 2026Nov 4, 20262 · $500,000
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Barlow CarroleedirectorJul 2018Nov 4, 2026none
Gemayel GeorgesdirectorMar 2015Nov 4, 20262 · $1.0M
Hudson Frederick M.directorApr 2012Nov 4, 20261 · $300,000
Newhall Charles W IIIdirectorApr 2012Nov 4, 2026none
Sensenig BethanydirectorAug 2023Nov 4, 20262 · $200,000
Earlier names on the record8, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton SUPN · research, not advice